Navigation Links
Vion Pharmaceuticals Files Plan With Nasdaq
Date:4/15/2008

NEW HAVEN, Conn., April 15 /PRNewswire-FirstCall/ -- Vion Pharmaceuticals, Inc. (Nasdaq: VION) today announced that it had filed a plan to achieve and sustain compliance with The Nasdaq Capital Market listing requirements, including the time frame for completion of the plan.

Previously, the Company announced that it had received a letter, dated March 24, 2008, from The Nasdaq Stock Market, Inc., notifying the Company that it does not comply with Marketplace Rule 4310(c )(3). As a result, Nasdaq Staff is reviewing the Company's plan to regain eligibility for continued listing on The Nasdaq Capital Market.

After the conclusion of Staff's review, if it is determined that the Company's plan does not adequately address the issues noted, Nasdaq will provide written notification that the Company's securities will be delisted. At that time, the Company may appeal the Staff's decision to a Nasdaq Listing Qualifications Panel.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its pro
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amylin Pharmaceuticals to Webcast First Quarter Results
2. Paloma Pharmaceuticals to Present at the American Association for Cancer Research
3. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Pharmaceuticals & Biotechs to Share Insights for Developing Leaders in a Fast-Paced, Competitive Industry
6. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
7. Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled Bipolar Trans Carotenoid Salts and Their Uses, for Its Family of First-In-Class Molecules
8. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
9. Microbia Announces Name Change to Ironwood Pharmaceuticals
10. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
11. Memory Pharmaceuticals Receives Nasdaq Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security LLC ... to develop and deliver a state-of-the-art laser system ... facility (ELI Beamlines), under construction in the Czech ... performance, the laser system, called the " High ...
(Date:8/27/2014)... DENVER , Aug. 27, 2014   MSC ... and patient safety, today announced the appointment of ... With 28 years of experience preparing companies ... in 2013 as Executive Vice President of Corporate Development ... healthcare performance improvement business , as well as corporate ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The Global ... in-depth study on the current state of the Trifluoroacetic ... provides a basic overview of the industry, including definitions, ... Chinese domestic market analysis are provided with a focus ... market. A comparison between the international and Chinese situation ...
(Date:8/27/2014)... -- Research and Markets  has announced the ... Polymer, Food & Beverage, Personal Care & Pharmaceutical) ... report to their offering. Lactic acid ... carbon atom. The main applications of lactic acid ... personal care product, and pharmaceutical industries. Lactic ...
Breaking Biology Technology:LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2
... Scimitar Equity, LLC issues a review ... entitled, "510k,Application Submitted for Xyfid(TM) and Priority ... Price Appreciation.", This review is available ... Pharmaceuticals is a New Jersey-based biotechnology company,dedicated ...
... 29 Zenobia Therapeutics, Inc.,(Zenobia) announced today ... award from The Michael J. Fox Foundation ... with potential to,fundamentally alter the course of ... Christopher Ross of Johns Hopkins University,Zenobia will ...
... July 29 ArunA Biomedical, Inc., the first,company ... and,services, announced today that William T. Sharp has ... to his ArunA leadership,responsibilities, Mr. Sharp has also ... succeeds ArunA founder Steven Stice, PhD, who will,remain ...
Cached Biology Technology:VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC 2Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2ArunA Biomedical Names William T. Sharp President and Chief Executive Officer 2
(Date:8/27/2014)... Orange, NJ. August 27, 2014. Using functional near ... differential brain activation patterns between people with multiple ... first MS study in which brain activation was ... task. The article, "Neuroimaging and cognition using functional ... published online on June 11 by Brain ...
(Date:8/27/2014)... of the HIV drug maraviroc, a new study from ... the drug was licensed in 2007, included mostly European-Americans, ... removing maraviroc from the body. The current study shows ... including nearly half of African-Americans end up with ... lack the protein even when given the same dose. ...
(Date:8/27/2014)... found in forests has created a thriving habitat for ... new University of Georgia study has found. , Japanese ... the early 1900s, is one of the most pervasive ... dozen states in the past century, particularly in the ... can survive in widely diverse ecosystems and has been ...
Breaking Biology News(10 mins):Kessler Foundation researchers publish first study of brain activation in MS using fNIRS 2Dosage of HIV drug may be ineffective for half of African-Americans 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3
... , April 27 ViroPharma Incorporated (Nasdaq: ... an open-label, multi-dose Phase 2 study to evaluate the ... administration of Cinryze™ (C1 esterase inhibitor [human)] in 24 ... was approved by the U.S. Food and Drug Administration ...
... , GLENDALE, Ariz. , April 27 Katie Michaels , ... of HBO,s "Cathouse" series, has announced she is returning to Phoenix to ... formidable Detroit Red Wings. , , , ... , , , ...
... 27, 2010 Imagine the luxury of,worldwide travel being virtually real ... lifestyle, cultural,historic and economic information on cities and destinations spanning our,universe. , ... Providing ... launching ArounderTouch -- a free,iPhone app -- in Italy on ...
Cached Biology News:ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 2ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 3ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 4ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 5Adult Star Katie Michaels Attending NHL Game 7 Red Wings vs. Coyotes 2ArounderTouch: A First-Class Ticket to Your Flights of Fancy 2ArounderTouch: A First-Class Ticket to Your Flights of Fancy 3
... serum is collected from fasted mixed breed, mixed ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG...
Whole blood is collected from canines (any breed, either sex), refrigerated within 6 hours, processed within 24 hours and frozen at -20C....
Designed for flow cytometric applications intended to identify...
Biology Products: